Where 10x Genomics Stands With Analysts
Portfolio Pulse from Benzinga Insights
In the last quarter, 10x Genomics (NASDAQ:TXG) received 2 bullish, 2 somewhat bullish, and 1 bearish analyst ratings. The company's average 12-month price target is $61.2, an increase of 11.27% from the previous average of $55.00.
September 19, 2023 | 6:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
10x Genomics received mostly positive analyst ratings in the last quarter, with an increased 12-month price target of $61.2.
The majority of analyst ratings for 10x Genomics in the last quarter were bullish or somewhat bullish, indicating a positive sentiment towards the company. The increase in the average 12-month price target suggests that analysts expect the company's stock price to rise in the future, which could potentially lead to an increase in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100